Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
Adding daclizumab to a tacrolimus-based therapy is safe but cannot further improve clinical efficacy.
Our study did not show an association between anabolic hormones and increased thyroid volume in women with prolactinoma.